Innovative approaches and patient care interventions achieved around a 40% improvement in outcomes for women with hypertensive disorders of pregnancy.
Systematic Review (n=1,710)
Do various interventions (pharmacological, lifestyle, mHealth) improve maternal and neonatal outcomes in pregnant women with or at risk of hypertensive disorders?
A systematic review of 6 RCTs highlights that early identification, standardized guidelines, and innovative approaches like mHealth and lifestyle interventions can improve outcomes in hypertensive disorders of pregnancy.
One of the worldwide public health concerns is hypertension. Globally, 14% and in India, about 10.3% of maternal mothers are affected by hypertension, based on UNICEF data. Hypertensive disorders of pregnancy are the most prevalent complication in maternal mothers and neonates. Gestational hypertension, chronic (or preexisting) hypertension, preeclampsia, preeclampsia superimposed on chronic hypertension, and eclampsia are among the conditions collectively referred to as hypertensive disorders in Pregnancy (HDPs), which are defined by elevated blood pressure (BP) during the prenatal period. Assessing risk factors and implementing appropriate monitoring facilitates the prediction of hypertensive disorders in pregnancy, which impacts maternal and neonatal outcomes. This review discusses causes, etiology, pathophysiology, treatment, and management of high blood pressure during pregnancy. A thorough database search was conducted, including the Cochrane Library, Scopus, and PubMed. The articles were retrieved based on the search terms combining “Maternal health,” “Hypertensive disorders of pregnancy,” and “Treatment and management” from 2020 to 2025. Enhancing postpartum care is crucial for achieving health targets. Antihypertensive medications are essential for managing hypertensive disorders of pregnancy in women. Consultation is especially required on certain contentious topics, such as when to begin therapy and whether laboratory testing and cardiovascular risk assessment are necessary before starting treatment. Rob 2 tool is used for risk assessment for the randomized control trial systematic review. It is necessary to provide vital measures to help healthcare providers navigate the remote monitoring system, which can be used in hypertensive management. Hence, a technology-based mobile application is necessary for monitoring blood pressure to ensure effective management. Trial registration: PROSPERO 2025 CRD420251008080.
P et al. (2026) conducted a systematic review in Hypertensive disorders of pregnancy (n=1,710). Innovative approaches and patient care (including low-dose aspirin, mHealth, and lifestyle modifications) vs. Standard care was evaluated on Maternal and neonatal outcomes and blood pressure control. Innovative approaches and patient care interventions achieved around a 40% improvement in outcomes for women with hypertensive disorders of pregnancy.